![]() Travere Therapeutics Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. | ![]() Genexine Genexine is a biotechnology company focused on the development and commercialization of immunotherapeutics and long-acting biologics. | ![]() JCR Pharmaceuticals JCR Pharmaceuticals is a company that specializes in the development of pharmaceutical products. | ||
Founding Date | Founding Date 2011 | Founding Date 1999 | Founding Date 1975 | Founding Date 2006 |
Type | Type Public | Type Public | Type Public | Type Private |
Tags | ||||
Locations | Locations San Diego, US HQ Dublin, IE | Locations Seongnam-si, KR HQ New York, US | Locations Ashiya, JP HQ Kobe, JP Kobe, JP Kobe, JP Kobe, JP | Locations Corsham, GB HQ |
Employees | Employees 46293% increase | Employees 86 | Employees 934 | Employees 903% decrease |
Valuation ($) | Valuation ($) 1.4 b | Valuation ($) N/A | Valuation ($) 533.9 m | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) $490.7m (FY, 2025) | Revenue (est.) ₩4.6b (FY, 2025) | Revenue (est.) ¥40.3b (FY, 2026) | Revenue (est.) N/A |
Cost of goods | Cost of goods $10.3m (FY, 2025) | Cost of goods (₩503.7m) (FY, 2025) | Cost of goods ¥7.6b (FY, 2026) | Cost of goods N/A |
Gross profit | Gross profit $480.4m (FY, 2025) | Gross profit ₩7.8b (FY, 2025) | Gross profit ¥32.7b (FY, 2026) | Gross profit N/A |
Net income | Net income ($25.5m) (FY, 2025) | Net income (₩27.2b) (FY, 2025) | Net income ¥2.2b (FY, 2026) | Net income N/A |

Genexine is a biotechnology company focused on the development and commercialization of immunotherapeutics and long-acting biologics.
View company
JCR Pharmaceuticals is a company that specializes in the development of pharmaceutical products.
View companyBath ASU (also known as Qualasept) is a pharmaceutical specials manufacturer.
View company